Adamas Pharma (ADMS) Misses Q4 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Adamas Pharma (ADMS) Misses Q4 EPS by 13c

Adamas Reports Fourth Quarter and Full Year 2020 Financial Results

February 23, 2021 4:03 PM EST

Fourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019

Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019

Second indication received February 2021 for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinsons disease patients experiencing OFF episodes

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended... More